Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Twist Bioscience Corporation
TWST | US
70.04
USD0.82
1.18%
TWST | US
Loading StockChartView...
About Twist Bioscience Corporation
Sector
Healthcare
Industry
Diagnostics & Research
Earnings date
30/06/2024
As of date
08/06/2026
Close
70.04
Open
70.71
High
70.82
Low
68.07
Twist Bioscience Corporation a synthetic biology company manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products including synthetic genes tools for sample preparation antibody libraries for drug discovery and development and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. The company was incorporated in 2013 and is headquartered in South San Francisco California.
View LessTWST | US
Risk
73.2
Sharpe
1.89
Luna's Score
61/100
Recommendation
Hold
Luna says (TWST | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
68.0%1 month
73.2%3 months
74.6%6 months
68.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
5.60
Debt to equity
0.18
Debt to assets
0.14
Ent. to EBITDA
-35.26
Ent. to rev.
8.63
PEG
-
Other Fundamentals
EBITDA
-156.67M
MarketCap
4.10B
MarketCap(USD)
4.10B
Div. yield
-
Op. margin
-54.00
Erngs. growth
-
Rev. growth
27.80
Ret. on equity
-38.36
Short ratio
10.73
Short perc.
19.40
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
19.90
Range1M
32.50
Range3M
38.98
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.89
Price X volume
97.71M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -35.26 | 12.67 | Cheaper |
| Ent. to Revenue | 8.63 | 44.00 | Cheaper |
| PE Ratio | - | 40.09 | - |
| Price to Book | 5.60 | 77.50 | Cheaper |
| Dividend Yield | - | 1.18 | - |
| Std. Deviation (3M) | 74.63 | 59.59 | Riskier |
| Debt to Equity | 0.18 | -14.36 | Expensive |
| Debt to Assets | 0.14 | 0.34 | Cheaper |
| Market Cap | 4.10B | 13.71B | Emerging |
